Nice first quarter results. Humira sales 3.11B vs. 2.64B last year. EPS and revenues topped expectations. They are making inroads to the Hep C market....let the stock rise and enjoy the profits. Between Abt and Abbvie the first quarter results have been excellent.
Nice results. Having Mylan shares also helped move the stock price. Letter from Miles to retirees was very positive and sounded as if company was in a good position to keep future earnings in line with their forecast. Thanks for posting about Abt...nice to see something other than spam.
Read it before your post....possible tank for reasons mention in the article and others, but not impressed with the article. Didn't go into Abbvie's pipeline and pcyc pipeline enough whick could provide upside. Think Abt is a better investment, but like Abbvie's dividend. I'll hold both and may sell covered calls only if Abbvie's stock price gets to previous highs (long shot). You are a long-term investor and not a trader. Are you going to sell.....based on this article.?
Abbvie just signed a license agreement with C2N to develop and commercialize anti tau antibodies for the treatment of Alzheimers. Is this the first step in another Abbvie takeover? At least they are expanding their neuroscience product line. Good move.
Insurance companies and medicare have a part in the decisions on drug presceiptions but Humira is still the number one doctor's choice and paid by the insurance companies and medicare; 7.22B in U.S. sales in 2014 (Bernstein Research as published in the WSJ). Humira doesn't go off patent until 12-2016 so I'd expect sales to continue the upward trend at least til then if not longer. We'll see if Humira is dead by 12-31-15. Wish we could bet on who is right. I'll keep your post and check in with you each quarter. I'll post it under Humira Sales.
For those who are interested, or do not know the regulations for biosimilars, go to the FDA CBER website and search for biosimilars guidelines (CBER = Center for Biologics Evaluation and Research). The Biosimilars guidelines link will take you to Guidance, Compliance and Regulation Information (Biologics). Then have some fun looking through all the documents. In short, biosimilars are held to the same standards as new drugs and will require the same amount of time, money and work as the original drug. As said before, there are no short cuts to drug approvals whether they are biosimilars or new drugs. Amgen, Boehriger Ingelheim, Novartis, Pfizer and Sumsung are developing biosimilars to Humira (Source Bernstein Research as published in the Wall Street Jounal). Even if one of the above companies get a biosimilar approval for Humira it will take time to penetrate Humiras market.....the Drs love Humira...
The nice move in stock price today was probably helped by an independent panel's recommendation to the FDA to unblind a cancer study in which imbruvica was used in combination with other drugs. Results demonstrated a signficant statistical increase in survival and without disease progression.
Typical jak.stat reply.....no data, no personal info, no awards or grants, published a few papers. Hasn't answered how far Amgen is along because he doesn't know (but they are very advanced!!). The one constant in all posts remains....the name calling and put downs.....some things never change. Based on your posts, anyone turned down "at your companies" (whatever that means) should consider themselves fortunate.
Thanks! Abbott's a good company. With ADD's constant reshuffling of management and cut backs you are a survivor. Good luck, hang in there and thanks for what you do in ADD.
As you know from previous posts I was on the Volwiler Society at Abbott for about 20 years (not at the lowest rung) until I retired. I received over $620,000 in NIH grants before joining Abbott and authored over 90 scientific articles. I received 4 Chairman awards from Abbott. Have you ever published??? Have you ever received NIH or NSF funding?? Did you ever receive a Chairman award? I consult today. Do you consult? You are a scientific entrepreneur....is that another way of saying you are unemployed? You are very vague about your background....seem unwilling to divulge any information.....characteristics associated with a shyster or ashamed of their background. Where is Amgen in terms of the Humira replacement? You didn't answer the question in the previous post. Are they in clinical trials? When they submit their NDA to the FDA it won't be fast tracked or receive priority review. So it will be several months before they get approval, if they get approval. Following approval it will take several months to significantly penetrate Abbott's market....that's the basis for the "2018 or so". You haven't contradicted any of my claims with factual information. All you do, on every post, is call people names or put them down. Certainly not the characteristics of a person of integrity or of a scientist......Clean up your mind, post with facts, act like a scientist....if you are.
So what if Amgen is very advanced (whatever "very advanced" means) in producting a Humira biosimilar. That doesn't mean it hasn't taken quite a while and a significant cost. There is no short cut in time or money in getting a biosimilar approved; it takes time and money....at least as much time and money as the original drug. No wishful thinking, I just know the facts for biological drug development and getting it to market. What your experience in biological drug development?? When will Amgen be to market with an adalimumab biosimilar? Bet you can't answer that. As usual your negative thinking obsures your mind.
There will be a high cost of entering the field of biosimilars. Biosimilars are produced by cells...the cells will have to be engineered, characterized, grown at large-scale, the product purified, the final product extensively characterized, be similar in efficacy, safety, half-life and all other characteristics associated with the original drug. All of these parameters are required for cells producing biologics; cells producing biosimilars will be held to the same standards and perhaps even more scrutinized. Biosimilars have changed the game by offerring competition to biologics where there has been no competition in the past.. Consequently prices will be more competitve than what currently is seen. It will take considerable time to get a biosimilar to market when the above is combined with Phase I, II and III studies. The effects of biosimilars on Abbvie is difficult to determine. Humira will be effected but probably not all indications if Phase studies are required on each indication. Analyists have estimated that Humira will start seeing significant competition in 2018 or so. Because of the high cost of biosimilar entry high revenue products will be targeted.
The presentation today was received well based on the 2+ upward move in the stock price. They reviewed how pycy was valued and stated that the next lowest bid was about 4% (about 840M) lower than their final bid; not 3B lower. Didn't listen to all the presentation, but guess it went over well. Now they have to execute their strategy.
You ask now what???? pcyc shareholders class action suit initiated against abbvie re. whether the buy out was priced fairly. Gonzales speaks at 8:30 CDT on March 12th. Webcast at www.abbvieinvestor.com. What were the script numbers? Haven't seen any script results for the past 2 weeks. Thought you were only a GLD owner; if so why are you on this board?
The pcyc buyout price resulted in a significant drop in the share price today. ABBV initiated a stock buy back last fall...I think it was a 5B buy back. I hope the company is buying the stock. They should help prop up the price. Did the company raise the dividend twice in anticipation of this reaction? The dividend is a major reason why many investors are holding onto the stock. There will probably will be a dead cat bounce tomorrow. HCV scripts will be out tomorrow. Hopefully that will help the stock price. It needs everything it can get.